Personal statement
Susan Currie obtained her PhD in Biochemistry (cellular signalling and molecular pharmacology) from the University of Glasgow in 1992 then spent two years at Lilly Research Laboratories, USA, where she studied the role of phospholipase A² in mast cell activation. She returned to the University of Glasgow in 1994 to join the then newly formed Clinical Research Initiative in heart disease and became a founder member of the school of cardiovascular studies in Glasgow. During this time she progressed from postdoctoral researcher to Principal Investigator examining the role of Calcium/calmodulin protein kinase ll (CaMKll) in cardiac hypertrophy and heart failure. She moved to the University of Strathclyde in 2005 as a Lecturer in Physiology & Pharmacology and established an independent cardiovascular signalling research group with principal interests in CaMKll modulation of cardiac calcium handling and cardiac inflammation. CaMKll as a therapeutic target in cardiac disease remains a key focus of research and characterising the actions of this enzyme is ongoing. More recent research interests include cardiotoxicity in the context of safety pharmacology as well as altered cardiovascular function in ageing.
Dr Currie is currently chair of the Scottish Cardiovascular Forum and full member of the Physiological Society and Biophysical Society, as well as being the Strathclyde University representative for the Physiological Society. She was made a Fellow of the Physiological Society in 2017 in recognition of her contribution to cardiovascular research and the discipline of Physiology. She currently teaches on a wide range of classes across both the MPharm and Biomedical Sciences programmes at the University of Strathclyde and coordinates classes on the MPharm programme. She was awarded Fellowship of the Higher Education Academy in 2008. She currently co-directs the collaborative MPharm programme between the University of Strathclyde and the International Medical University (IMU) in Kuala Lumpur, acting as MPharm representative on the internationalisation committee and is Deputy Director of the MPharm programme at the University of Strathclyde.
Professional activities
- Heart Research UK Scotland annual event
- Speaker
- 7/6/2021
- Novel off-target effects of doxorubicin on cardiovascular gap-junctional proteins
- Contributor
- 5/2/2021
- Scottish Cardiovascular Forum 2021
- Organiser
- 2/2021
- Assessment of the cardiac work-loop to identify drug-induced changes in contractility using rat papillary muscles (Coventry University)
- Examiner
- 2021
- Suppressor of cytokine signalling 3 (SOCS3) turnover and regulation of human saphenous vein smooth muscle cell signalling and function (University of Bradford)
- Examiner
- 2021
- Experimental Biology
- Organiser
- 2021
More professional activities
Projects
- Remodelling of E-C coupling in heart failure with preserved ejection fraction (HFpEF)
- Currie, Susan (Co-investigator)
- 01-Jan-2021 - 30-Jan-2024
- Cross-examining interplay between High Mobility Group Box 1 (HMGB1) and coagulation: Defining a role for G protein-coupled receptors (GPCRs) in this complex Coag-Inflammatory nexus
- BOSAKHAR, Zainab Y H A H A (Post Grad Student) Currie, Susan (Co-investigator) Plevin, Robin (Academic) Cunningham, Margaret Rose (Principal Investigator)
- 01-Jan-2020 - 30-Jan-2023
- Doctoral Training Partnership 2020-2021 University of Strathclyde | Geiser, Angéline
- Gould, Gwyn (Principal Investigator) Currie, Susan (Co-investigator) Geiser, Angéline (Research Co-investigator)
- 01-Jan-2020 - 01-Jan-2024
- Investigating connexin 43 expression in adult cardiac fibroblasts
- Currie, Susan (Principal Investigator)
- 31-Jan-2019 - 30-Jan-2019
- Investigating the biomolecular complexity of drug-induced cardiotoxicity by fingerprinting single cell and cardiac spheroid mass spectral information using Time-of-flight Secondary Ion Mass Spectrometry (TOF-SIMS)
- Cunningham, Margaret Rose (Principal Investigator) Veerman, Ben (Post Grad Student) Johnston, Blair (Co-investigator) Currie, Susan (Co-investigator)
- The aim of this project is to significantly advance upon ongoing efforts in understanding drug-induced cardiotoxicity not only at the single cell level but in a multicellular model that may better reflect the cellular microenvironment of the heart. Extending studies to assess the metabolite changes in the multicellular environment in response to cancer therapeutics may reveal events integral to toxicity which may lead to new knowledge to develop ways to minimise or prevent cellular toxicity in the cardiac niche.
- 01-Jan-2019 - 28-Jan-2022
- Investigating the translational application of CaMKII as a biomarker for cobalt cardiotoxicity
- Currie, Susan (Principal Investigator) Grant, Mary (Co-investigator) Tate, Rothwelle (Co-investigator)
- 01-Jan-2019 - 31-Jan-2021
More projects
Address
Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing
Hamnett Wing
Location Map
View University of Strathclyde in a larger map